Testing a new drug for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called VBC108 in people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that is advanced or has spread and cannot be removed with surgery.
- You must be 18 years or older.
- You must be well enough to be up and about for at least half of your waking hours.
- Your life expectancy must be at least 12 weeks.
- You must have a tumor sample available from a previous biopsy or be willing to have a new biopsy.
- You must not have had certain types of targeted therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug for people with advanced solid tumors that have spread or can't be removed. The drug targets specific proteins on cancer cells to try to shrink or slow the cancer.
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
This trial tests a new drug called VIB305 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if VIB305 is safe and how it affects the tumors.
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.